Department of Cardiac Surgery, Sheba Medical Center at Tel Hashomer, 52621, Ramat Gan, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Cardiovasc Diabetol. 2023 Mar 31;22(1):77. doi: 10.1186/s12933-023-01810-x.
Diabetes mellitus (DM) type 2 is an independent risk factor for atrial fibrillation (AF). Surgical ablation or "maze procedure" is an option for patients with AF undergoing concomitant or isolated cardiac surgery. The aim of this study was to evaluate the impact of DM type 2 on early and long-term outcomes of patients following surgical AF ablation.
We performed an observational cohort study in Israel's largest tertiary care center. All data of patients who underwent surgical AF ablation, between 2006 and 2021 were extracted from our departmental database. Patients were divided into Group I (non-diabetic patients) and Group II (DM type 2 patients). We compared the two groups with respect to freedom from recurrent atrial arrhythmia, and mortality rate.
The study population included 606 patients. Group I (non-DM patients), consisting of 484 patients, and Group II (DM type 2 patients), comprised 122 patients. Patients with DM were older, had more hypertension and incidence of cerebrovascular accident (CVA)/transient ischemic attack (TIA), higher EuroSCORE (p < .05 for all), and a longer bypass time-130 ± 40 vs. 122 ± 36 min (p = 0.028). The mean follow-up duration was 39.0 ± 22.7 months. Freedom from atrial fibrillation was similar between the non-DM and DM type 2 groups after a 1-year follow-up, 414 (88.2%) vs. 101 (87.1%) (p = 0.511), after a 3-year follow-up, 360 (86.3%) vs. 84 (79.9%) (p = 0.290) and after a 5-year follow-up, 226 (74.1%) vs. 55 (71.5%) (p = 0.622) respectively. Furthermore, 1- and 3-year mortality was similar between non-DM and DM type 2 groups, 2.5% vs. 4.9%, (p = 0.226) and 5.6% vs. 10.5% (p = 0.076) respectively. 5-year mortality was higher in Group II (DM type 2 patients) compared with Group I (non-DM patients), 11.1% vs. 23.4% (p = 0.009).
Surgical ablation had a high success rate, with freedom from recurrent atrial arrhythmia at 1- 3- and 5- years follow-up in both the DM type 2 and non-DM groups. Furthermore,1- and 3-year mortality after surgical ablation was also similar in both groups. However, 5-year mortality was higher in the DM type 2 group.
2 型糖尿病是心房颤动(AF)的独立危险因素。对于同时或单独接受心脏手术的 AF 患者,手术消融或“迷宫手术”是一种选择。本研究旨在评估 2 型糖尿病对接受 AF 手术消融患者的早期和长期结局的影响。
我们在以色列最大的三级护理中心进行了一项观察性队列研究。从我们的部门数据库中提取了 2006 年至 2021 年间接受 AF 手术消融的所有患者的数据。患者分为 I 组(非糖尿病患者)和 II 组(2 型糖尿病患者)。我们比较了两组患者的复发性房性心律失常和死亡率。
研究人群包括 606 名患者。I 组(非 DM 患者)由 484 名患者组成,II 组(2 型糖尿病患者)由 122 名患者组成。糖尿病患者年龄较大,高血压和中风/短暂性脑缺血发作(CVA/TIA)发生率更高,欧洲心脏手术风险评分(EuroSCORE)更高(p<0.05 ),并且体外循环时间较长-130±40 分钟与 122±36 分钟(p=0.028)。平均随访时间为 39.0±22.7 个月。在 1 年随访时,非 DM 组和 DM 2 型组的房颤无复发率相似,分别为 414(88.2%)和 101(87.1%)(p=0.511),在 3 年随访时,分别为 360(86.3%)和 84(79.9%)(p=0.290),在 5 年随访时,分别为 226(74.1%)和 55(71.5%)(p=0.622)。此外,非 DM 组和 DM 2 型组的 1 年和 3 年死亡率相似,分别为 2.5%和 4.9%(p=0.226)和 5.6%和 10.5%(p=0.076)。与 I 组(非 DM 患者)相比,II 组(DM 2 型患者)的 5 年死亡率更高,分别为 11.1%和 23.4%(p=0.009)。
手术消融具有很高的成功率,在 DM 2 型和非 DM 组中,1 年、3 年和 5 年随访时复发性房性心律失常的无复发率均较高。此外,两组患者术后 1 年和 3 年的死亡率也相似。然而,DM 2 型组的 5 年死亡率较高。